Biologic Specimen and Data Repository Information Coordinating Center
Home > Studies > PEACE

Resources Available

Specimens and Study Datasets

Materials Available

PLASMA 41,699
SERUM 21,015
URINE 14,134

Study Documents

PDF Data Dictionary (PDF - 84.3 KB)
PDF Data Dictionary Ancillary (PDF - 46.4 KB)
PDF Follow-up Visit (PDF - 120.6 KB)
PDF List of Publications (PDF - 84.4 KB)
PDF Pre-Randomization Information (PDF - 107.4 KB)
PDF Protocol (PDF - 126.4 KB)
PDF Randomization Visit (PDF - 142.4 KB)
PDF Screening Form (PDF - 125.0 KB)
Ancillary Study Documentation (HTML )
PDF PEACE LADS Readme (PDF - 377.2 KB)

Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message.

If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

Clinical Trials URL:
Study Type: Clinical Trial
Prepared on October 13, 2008
Last Updated on January 15, 2008
Study Dates: November 1995 - June 2005
Consent: Restricted Consent
Consent Restrictions: Research restricted to predictors of coronary heart disease progression
Commercial Use Restrictions: No
NHLBI Division: DCVS
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information


To conduct a trial to test the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy.


Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.


The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).


In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. (NEJM 2004;351:2058-2068)